ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1179

Differential Cytokine Profiles for Non-Human Leukocyte Antigen (Non-HLA) and HLA Antibodies in Pediatric Kidney Transplantation

Session Information

  • Pediatric Nephrology - I
    October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1600 Pediatric Nephrology


  • Pearl, Meghan, UCLA, Los Angeles, California, United States
  • Grotts, Jonathan, UCLA, Los Angeles, California, United States
  • Rossetti, Maura, UCLA, Los Angeles, California, United States
  • Zhang, Qiuheng Jennifer, UCLA, Los Angeles, California, United States
  • Weng, Patricia L., UCLA, Los Angeles, California, United States
  • Elashoff, David, UCLA, Los Angeles, California, United States
  • Reed, Elaine F., UCLA, Los Angeles, California, United States
  • Tsai, Eileen W., Duke University, Durham , North Carolina, United States

The inflammatory profiles associated with human leukocyte antigen (HLA) and non-HLA antibodies to G-protein coupled receptors in kidney transplant recipients (KTRs) are unknown. We have recently shown that angiotensin II type 1 receptor antibody (AT1R-Ab) and Endothelin-1 Type A receptor antibody (ETAR-Ab) are prevalent and associated with poor outcomes in pediatric KTRs. We aimed to compare inflammatory profiles of AT1R-Ab, ETAR-Ab, and HLA donor specific antibodies (DSA) in pediatric KTRs.


233 blood samples from 65 pediatric KTRs were analyzed. ETAR-Ab (ELISA), AT1R-Ab (ELISA), HLA DSA (Luminex), and TNF-α, IL-1β, IL-8, IFN-γ, IL-17, IL-6 (Luminex) were measured in blood samples taken at 6 months (m), 12m, and 24m post-transplant and during episodes of rejection. Based on a receiver operating curve analysis, > 10 and >17 units/ml was considered positive for ETAR-Ab and AT1R-Ab and >1000 MFI was considered positive for HLA DSA.


HLA DSA, AT1R-Ab, and ETAR-Ab were positive in 25 (11%), 92 (40%), and 50 (22%) of samples respectively. 96% of samples positive for ETAR-Ab also had AT1R-Ab. All three antibodies were associated with elevations in IL-8 while AT1R-Ab was associated with elevations in all 6 cytokines (Table 1).


AT1R-Ab is associated with a distinct inflammatory profile compared to HLA DSA or ETAR-Ab in the first 2 years post-transplant. Further studies are needed to understand the distinct mechanisms of HLA vs. non-HLA antibody mediated allograft injury.


  • Private Foundation Support